Compare Humana Inc (HUM) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Unilever plc — how do they compare? Humana Inc trades at $431.03 (market cap $46.49B), while Unilever plc trades at $62.26 (market cap $131.63B). The key difference: Unilever plc is far larger — about 2.8× Humana Inc's market cap, and Unilever plc pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 51 Days and Unilever plc for 112 Days on average.
| HUM | UL | |
|---|---|---|
Market Cap | $46.49B | $131.63B |
Volume | 2,567,704 | 2,978,741 |
Sector | Health | Consumer Staples |
52-Week High | $431.03 | $74.59 |
52-Week Low | $163.67 | $55.05 |
Typical Hold Time | 51 Days | 112 Days |
Enterprise Value | $53.84B | $156.65B |
Dividend Yield | 0.91% | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 2.37% today, with a bullish technical outlook supported by moving averages and strong institutional interest. The company shows steady revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent analyst upgrades and a $460.74 consensus price target suggest upside potential, while Medicare Advantage plan changes and fiduciary scrutiny present near-term headwinds.
The stock offers value with a low P/S ratio of 0.32x and consistent earnings beats, but faces margin pressure and regulatory risks. Institutional accumulation and positive technicals support a constructive outlook, though investors should monitor enrollment trends and cost management execution for sustained growth.
Unilever (UL) trades at $61.94, up 1.57% with a bullish technical signal. The company shows strong profitability with 18.32% net margins and 54.56% ROE, though recent earnings have missed expectations. Valuation ratios include a P/E of 21.59 and P/S of 2.38. The company is undergoing strategic transformation with its food business merger with McCormick, while facing regulatory scrutiny and mixed analyst sentiment.
UL presents a balanced risk-reward with strong emerging market exposure and portfolio streamlining offering growth potential. However, earnings misses, regulatory challenges, and mixed analyst ratings suggest cautious optimism. The stock's low beta provides defensive characteristics amid market volatility, but execution risks and competitive pressures remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
